You are here

For the media

Contact Caroline Marin at 612-624-5680 or at to request an interview with an expert from any one of our health sciences programs. She will work with our entire public relations team to ensure your request is handled immediately.

Frequent genetic changes in receptor related to prostate cancer care could cause treatment resistance

Wednesday, November 30, 2016

Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.

The paper is published in the latest issue of Nature Communications.

“We knew genetic rearrangements in the androgen receptor occurred in laboratory models of prostate cancer progression, and this could promote therapeutic resistance,” said Scott Dehm, Ph.D., associate professor in the Department of Laboratory Medicine and Pathology in the University of Minnesota Medical School and a member of the Masonic Cancer Center, University of Minnesota. “An outstanding question was if this reflected a mechanism of therapeutic resistance in prostate cancer patients, or whether it was unique to laboratory models.”

University of Minnesota named a Udall Center of Excellence in Parkinson's Disease Research, receives $9.07 million over five years

Thursday, September 22, 2016

The University of Minnesota has been named a Udall Center of Excellence in Parkinson’s Disease Research, joining nine other centers around the country and with that distinction was awarded a National Institutes of Health-funded grant totaling $9.07 million over the next five years to improve the lives of patients with Parkinson’s disease.